Systemic drugs that harm the eye
Many drugs prescribed by physicians, neurologists and urologists damage the eye, and the ophthalmologist is often the first to notice. A small number of drug and toxicity pairs come up again and again in examinations because each has a characteristic pattern and, for some, a UK monitoring rule. This lesson groups them by the part of the eye they injure, explains why each causes the pattern it does, and sets out what monitoring is recommended.
A map of drug toxicity
Drugs reach the eye through its blood supply and tend to injure the tissue where they concentrate or where their pharmacological action lands. It helps to learn them from front to back.
| Drug | Used for | Ocular effect | UK monitoring |
|---|---|---|---|
| Amiodarone | Arrhythmias | Vortex keratopathy; rarely optic neuropathy | None routine; stop if optic neuropathy |
| Corticosteroids | Inflammation | Posterior subcapsular cataract, raised pressure | Pressure checks if long term or at risk |
| Tamsulosin | Prostatic enlargement | Intraoperative floppy iris syndrome | Tell the cataract surgeon |
| Topiramate | Epilepsy, migraine | Acute myopia and bilateral angle closure | None; warn the patient |
| Bisphosphonates | Osteoporosis | Uveitis, scleritis, episcleritis | None |
| Hydroxychloroquine | Lupus, rheumatoid arthritis | Bull's eye maculopathy | Annual OCT and autofluorescence after 5 years |
| Vigabatrin | Epilepsy, infantile spasms | Irreversible concentric field loss | Visual fields before treatment and every 6 months |
| Tamoxifen | Breast cancer | Crystalline maculopathy | None routine |
| Sildenafil | Erectile dysfunction | Blue-tinged vision; possible optic neuropathy | None |
| Digoxin | Atrial fibrillation, heart failure | Yellow-tinged vision | None; suspect toxicity |
| Ethambutol | Tuberculosis | Optic neuropathy | Visual acuity before treatment; report symptoms |
| Isotretinoin | Severe acne | Dry eye, poor night vision, raised intracranial pressure | None routine |
Cornea and lens
Amiodarone causes vortex keratopathy, also called cornea verticillata: fine golden-brown lines in the basal corneal epithelium that swirl out from a point in the lower cornea like a whorl. Amiodarone belongs to a group of drugs whose molecules have both a charged and a fatty end. These enter lysosomes in the epithelial cells and bind to lipids, forming complexes that the cell cannot break down. As the loaded cells migrate inwards from the limbus during normal epithelial turnover, they trace out the whorl. The deposits are bilateral, do not stain with fluorescein, and rarely cause more than haloes around lights. They are not a reason to stop the drug, and they fade after it is withdrawn.
The same pattern is produced by chloroquine and hydroxychloroquine, indometacin, chlorpromazine and tamoxifen, and by the glaucoma drop netarsudil. It also occurs in Fabry disease, an X-linked lysosomal storage disorder, which is the diagnosis to consider when a patient with a whorl keratopathy is taking none of these drugs.
Amiodarone can also, much less often, cause an optic neuropathy with slowly progressive loss of vision and disc swelling, usually within the first year of treatment. The BNF states that if vision is impaired, or optic neuritis or optic neuropathy occurs, amiodarone must be stopped to prevent blindness.
Corticosteroids by any route cause posterior subcapsular cataract and can raise intraocular pressure. Both are explained in the lesson on anti-inflammatory drugs.
Iris, angle and uvea
Tamsulosin relaxes smooth muscle in the prostate by blocking alpha-1A adrenoceptors. The iris dilator muscle has the same receptor subtype. With long-term blockade the dilator loses tone and may atrophy, and during cataract surgery the iris behaves abnormally. This is intraoperative floppy iris syndrome (IFIS), defined by three signs:
- a flaccid iris that billows in the normal flow of irrigating fluid,
- a tendency for the iris to prolapse through the surgical incisions,
- a pupil that progressively constricts during the operation.
A small, unstable pupil makes complications such as posterior capsule rupture more likely. Tamsulosin has by far the strongest association; less selective alpha blockers such as alfuzosin and doxazosin cause it less often. Stopping the drug before surgery does not reliably prevent it. What matters is that the surgeon knows in advance, so the question about alpha blockers belongs in every pre-operative cataract assessment. The surgeon can then use phenylephrine or adrenaline in the anterior chamber, iris hooks or a pupil expansion ring.
Topiramate causes a rare idiosyncratic reaction in which fluid collects in the choroid and ciliary body. The swollen ciliary body rotates forwards, pushing the lens and iris ahead of it. Two things follow. The lens moves forwards, so the eye suddenly becomes short-sighted. The iris is pushed against the drainage angle, so the pressure rises. The result is acute myopia with secondary angle closure, almost always in both eyes at once, and typically within the first few weeks of starting the drug or increasing the dose. The BNF advises seeking specialist advice, lowering the pressure and stopping topiramate as rapidly as feasible.
Drugs with antimuscarinic or sympathomimetic actions can precipitate ordinary pupil-block angle closure in a predisposed eye by dilating the pupil. Bisphosphonates such as alendronic acid can provoke inflammation: anterior uveitis, scleritis and episcleritis.
Retina: hydroxychloroquine
Hydroxychloroquine binds to melanin and accumulates in the retinal pigment epithelium, where it stays for a long time and damages the cell's lysosomes. The pigment epithelium can then no longer digest the outer segments that photoreceptors shed each day, and the photoreceptors above it die. The damage begins in a ring around the fovea and spares the foveal centre until late. Seen with an ophthalmoscope, a ring of pale atrophy around a darker centre is a bull's eye maculopathy, but by the time that is visible vision is already lost. In patients of Asian descent the ring may lie further out, near the arcades.
The retinopathy is irreversible and can go on progressing after the drug is stopped, because the drug clears so slowly. Everything therefore depends on detecting it before symptoms, on imaging. Retinopathy is more common than once thought: about 7.5% of people who have taken the drug for more than five years show it. The risk rises with:
- dose above 5 mg/kg/day,
- duration of treatment beyond five years,
- impaired renal function (eGFR below 60 mL/min/1.73 m2), since the drug is cleared by the kidney,
- concurrent tamoxifen.
The Royal College of Ophthalmologists' 2020 recommendations, summarised in the BNF, set out UK monitoring. A baseline examination is no longer recommended. Annual monitoring starts after 5 years of treatment, or after 1 year if one of the additional risk factors is present. Chloroquine is more toxic, and monitoring starts after 1 year. Each visit uses two imaging tests: spectral-domain optical coherence tomography and widefield fundus autofluorescence. Visual field testing and multifocal electroretinography are added only if the imaging is abnormal. Toxicity is definite when two tests show matching abnormalities, and the decision to stop the drug rests with the prescribing physician.
Retina: vigabatrin, tamoxifen, sildenafil and digoxin
Vigabatrin is an antiepileptic that raises levels of the inhibitory transmitter GABA. It is toxic to the peripheral retina and causes bilateral concentric constriction of the visual fields. The BNF states that about one-third of patients are affected, that onset varies from 1 month to several years after starting, and that in most cases the defect persists after the drug is stopped. Because the loss starts in the periphery, patients do not notice it. The BNF therefore advises visual field testing before treatment and at 6-month intervals, and urgent ophthalmological review for any new visual symptom.
Tamoxifen can cause a crystalline maculopathy, with fine glistening crystals at the macula. It also causes cataract and, rarely, corneal deposits.
Sildenafil inhibits phosphodiesterase type 5 in vascular smooth muscle. It also partly inhibits the closely related type 6 enzyme, which photoreceptors use in phototransduction. The effect is a transient disturbance of vision after a dose: a blue tinge (cyanopsia), increased sensitivity to light and blurring. It is dose related and reversible. Cases of non-arteritic anterior ischaemic optic neuropathy have been reported after sildenafil, though a causal link is not established. The BNF lists a history of that condition, and hereditary degenerative retinal disorders, as contraindications, and advises stopping the drug if sudden visual impairment occurs.
Digoxin in toxic concentrations disturbs colour vision. The classic symptom is xanthopsia, a yellow tinge to everything, but green or blue tinges, blurred or snowy vision, flickering lights and central scotomas are also described. The presumed mechanism is inhibition of the sodium-potassium pump in photoreceptors, with cones affected most. Visual symptoms in a patient on digoxin should prompt a check for toxicity. They usually resolve within a week or two of stopping.
Isotretinoin is a vitamin A derivative that shrinks sebaceous glands, including the meibomian glands of the eyelid. The tear film loses its oil layer, causing dry eye, blepharitis and intolerance of contact lenses. It can also impair dark adaptation and night vision, and rarely causes idiopathic intracranial hypertension with papilloedema. The BNF advises that visual disturbances require expert referral and possible withdrawal.
Optic nerve: ethambutol
Ethambutol is part of standard four-drug treatment for tuberculosis and is a direct toxin to the optic nerve. The mechanism is thought to involve chelation of copper and zinc, which the mitochondria of the nerve fibres need. The fibres that carry central vision, the papillomacular bundle, are the most vulnerable.
The picture is a bilateral, painless, symmetrical loss of central vision, usually developing between 2 and 8 months into treatment. Loss of red-green colour discrimination is often the first sign. The field defect is a central or caecocentral scotoma. The optic discs look normal at first, because the damage is behind the eye, and turn pale later. Because both nerves are affected equally there may be no relative afferent pupillary defect.
Toxicity is dose related: under 1% of patients at 15 mg/kg/day or less, and about 5 to 6% at 25 mg/kg/day. The drug is excreted by the kidneys, so renal impairment raises the risk. The BNF requires renal function to be checked and visual acuity to be tested with a Snellen chart before treatment, and lists optic neuritis and poor vision as contraindications. Patients are told to stop the drug and seek advice at once if their vision changes. Ethambutol is used with caution in young children and others who cannot report visual symptoms. The BNF states that early discontinuation is almost always followed by recovery of eyesight. Published series are less optimistic, with recovery often partial, so prompt recognition matters.
Summary
- Amiodarone causes a harmless, reversible vortex keratopathy and, rarely, an optic neuropathy that requires the drug to be stopped.
- Tamsulosin causes intraoperative floppy iris syndrome: a billowing iris, iris prolapse and progressive miosis; stopping the drug does not reliably prevent it.
- Topiramate causes bilateral acute myopia and angle closure from ciliochoroidal effusion, usually within weeks of starting.
- Hydroxychloroquine causes an irreversible bull's eye maculopathy; risk rises above 5 mg/kg/day, after 5 years, with renal impairment and with tamoxifen.
- UK monitoring for hydroxychloroquine is annual OCT and fundus autofluorescence after 5 years, or after 1 year with risk factors.
- Vigabatrin causes irreversible concentric visual field loss in about one-third of patients; fields are tested before treatment and every 6 months.
- Ethambutol causes a dose-related bilateral optic neuropathy with central scotomas and red-green colour loss; acuity is tested before treatment.
- Sildenafil causes transient blue-tinged vision through inhibition of retinal phosphodiesterase type 6.
- Digoxin toxicity causes yellow-tinged vision (xanthopsia).
- Corticosteroids cause posterior subcapsular cataract and raised pressure; bisphosphonates can cause uveitis and scleritis.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.